Industry news

  1. Image of the Year shows exceptional responses to cancer treatment

    Industry NewsThe dramatic before-and-after images show eight men's incredible response to cutting-edge treatment. 

    Read more »
  2. New study suggests men and women may benefit differently from some immunotherapy medications

    News updateThe study showed that the relative survival gain almost doubled in men, compared to female patients, regardless of the type of cancer and drugs given.

    Read more »
  3. Keytruda-chemo combination shows beneficial response in treating metastatic NSCLC

    Industry NewsResearchers say the addition of Keytruda (pembrolizumab) in this study almost doubled the response rate of chemo for patients with NSCLC.

    Read more »
  4. A wearable device for opioid withdrawal?

    Industry NewsThe FDA has approved a wearable device to treat withdrawal symptoms such as agitation, anxiety, depression, and opiate cravings.

    Read more »
  5. T-cell therapy yields objective response rate of 52% in lymphoma (DLBCL) patients

    Industry NewsThe 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%.

    Read more »
  6. Full marketing authorisation for blinatumomab

    Industry NewsThe latest approval renders the previous 'temporary approval' a full approval, without further results needed.

    Read more »
  7. Response to Keytruda (pembrolizumab) better in older patients, study suggests

    Industry NewsResearchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.

    Read more »
  8. New immunotherapy shows reduction in tumor size for NSCLC patients

    Industry NewsIt’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.

    Read more »
  9. Efficacy issues with Keytruda and Tecentriq in some clinical trials

    The Food and Drug Administration (FDA) has drawn attention to efficacy issues associated with Keytruda or Tecentriq in some clinical trials - patients and healthcare professionals should take note.

    Industry news
     

    Read more »
  10. Tagrisso gets the green light for first-line lung cancer treatment in Europe

    Industry NewsTagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment. 

    Read more »
Posts loader

Just one thing before you continue

Our service contains information about acquiring treatments that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

No, take me out of here.
CONTINUE